Aclaris Therapeutics 计划于2026年第四季度启动Modzatinib针对Lp的阶段性多部分2B期临床试验

美股速递
Aug 07

Aclaris Therapeutics, Inc. 宣布,公司预计将在2026年第四季度启动一项针对Lp的Modzatinib阶段性多部分2B期临床试验。这一计划标志着该药物研发进程中的重要里程碑,预示着其临床开发进入更深入的阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10